Global pharmaceutical giant Boehringer Ingelheim has signed a new five-year ... Brands include Frontline, Jardiance and NexGard. The firm’s revenue last year was approximately $30.1 billion ...

Boehringer Ingelheim has released data on its patient reach, sales, and investments during 2024, and is looking ahead to the company’s anticipated offerings for the rest of 2025. In a press release on ...

Markus Schümmelfeder has spent more than a decade looking for ways to help biopharmaceutical giant Boehringer Ingelheim exploit digital and data. He joined the company in February 2014 as ...

Boehringer Ingelheim Korea has marked a turning point ... the company is focusing on parasiticides as a core pipeline, with products like NexGard Spectra and NexGard Combo receiving positive responses ...

The product donation of NexGard® PLUS chews includes monthly flea, tick, heartworm disease, roundworm, and hookworm protection from Boehringer Ingelheim. "At Boehringer Ingelheim, we are deeply ...

Feb. 05, 2025 (GLOBE NEWSWIRE) -- Greater Good Charities is teaming up with Boehringer Ingelheim for the global nonprofit’s annual Shelter Bowl event. The event will donate millions of nutritious pet ...

Boehringer Ingelheim announced it will buy Nerio Therapeutics for $1.3 billion Monday morning. The German drugmaker is bolstering its immuno-oncology pipeline by adding the San Diego-based drug ...

Milestones reached in cardiovascular, renal, metabolic health (CRM), and oncology Further data read-outs expected in 2024 in oncology, mental health, and pulmonary fibrosis Strong first half net sales ...

WASHINGTON — A federal judge ruled against Boehringer Ingelheim’s challenge to the new Medicare drug price negotiation program, handing the pharmaceutical industry its latest in a string of ...

April 26, 2024 /PRNewswire/ -- Boehringer Ingelheim, the largest animal health company in Georgia and its NexGard ® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) product ...